These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1346 related articles for article (PubMed ID: 26878173)

  • 21. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.
    Shi X; Liu R; Qu S; Zhu G; Bishop J; Liu X; Sun H; Shan Z; Wang E; Luo Y; Yang X; Zhao J; Du J; El-Naggar AK; Teng W; Xing M
    J Clin Endocrinol Metab; 2015 Apr; 100(4):E632-7. PubMed ID: 25584719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
    Ricarte-Filho JC; Ryder M; Chitale DA; Rivera M; Heguy A; Ladanyi M; Janakiraman M; Solit D; Knauf JA; Tuttle RM; Ghossein RA; Fagin JA
    Cancer Res; 2009 Jun; 69(11):4885-93. PubMed ID: 19487299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanistic Insights of Thyroid Cancer Progression.
    Leandro-García LJ; Landa I
    Endocrinology; 2023 Aug; 164(9):. PubMed ID: 37503738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of EIF1AX in thyroid cancer tumourigenesis and progression.
    Simões-Pereira J; Moura MM; Marques IJ; Rito M; Cabrera RA; Leite V; Cavaco BM
    J Endocrinol Invest; 2019 Mar; 42(3):313-318. PubMed ID: 29968046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A six-genotype genetic prognostic model for papillary thyroid cancer.
    Shen X; Liu R; Xing M
    Endocr Relat Cancer; 2017 Jan; 24(1):41-52. PubMed ID: 27875244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
    Latteyer S; Tiedje V; König K; Ting S; Heukamp LC; Meder L; Schmid KW; Führer D; Moeller LC
    Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression.
    Ghossein RA; Katabi N; Fagin JA
    J Clin Endocrinol Metab; 2013 Aug; 98(8):E1414-21. PubMed ID: 23775351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic Profiling of Aggressive Thyroid Cancer in Association With its Clinicopathological Characteristics.
    Kim JH; Jeong JY; Seo AN; Park NJ; Kim M; Park JY
    In Vivo; 2022; 36(1):111-120. PubMed ID: 34972706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
    Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
    Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
    Gandolfi G; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A; Sancisi V
    Eur J Endocrinol; 2015 Apr; 172(4):403-13. PubMed ID: 25583906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.
    Kunstman JW; Juhlin CC; Goh G; Brown TC; Stenman A; Healy JM; Rubinstein JC; Choi M; Kiss N; Nelson-Williams C; Mane S; Rimm DL; Prasad ML; Höög A; Zedenius J; Larsson C; Korah R; Lifton RP; Carling T
    Hum Mol Genet; 2015 Apr; 24(8):2318-29. PubMed ID: 25576899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
    Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
    Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas.
    Marques IJ; Moura MM; Cabrera R; Pinto AE; Simões-Pereira J; Santos C; Menezes FD; Montezuma D; Henrique R; Rodrigues Teixeira M; Leite V; Cavaco BM
    Clin Endocrinol (Oxf); 2017 Oct; 87(4):394-399. PubMed ID: 28502101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases.
    Xu B; David J; Dogan S; Landa I; Katabi N; Saliba M; Khimraj A; Sherman EJ; Tuttle RM; Tallini G; Ganly I; Fagin JA; Ghossein RA
    Histopathology; 2022 Jan; 80(2):322-337. PubMed ID: 34449926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy.
    Boruah M; Gaddam P; Agarwal S; Mir RA; Gupta R; Sharma MC; S Deo SV; Nilima N
    J Cancer Res Ther; 2023; 19(2):312-320. PubMed ID: 37006068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
    Liu X; Bishop J; Shan Y; Pai S; Liu D; Murugan AK; Sun H; El-Naggar AK; Xing M
    Endocr Relat Cancer; 2013 Aug; 20(4):603-10. PubMed ID: 23766237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Recurrent Altered Genes in Chinese Patients With Anaplastic Thyroid Cancer.
    Zhang L; Ren Z; Su Z; Liu Y; Yang T; Cao M; Jiang Y; Tang Y; Chen H; Zhang W; Gong R; Wei T; Peng Y; Liu B; Zhang W; Yang L; Hu Y; Li Z; Zhu J; Xu H; Shu Y; Luo H
    J Clin Endocrinol Metab; 2021 Mar; 106(4):988-998. PubMed ID: 33428730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DICER1 Mutations Do Not Always Indicate Dismal Prognosis in Pediatric Poorly Differentiated Thyroid Carcinomas.
    Yegen G; Altay AY; Yılmaz İ; İşcan Y; Sormaz İC; Aksakal N; Önder S; Mete Ö
    Endocr Pathol; 2023 Sep; 34(3):279-286. PubMed ID: 37574466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
    Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
    [No Abstract]   [Full Text] [Related]  

  • 40. Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations.
    Barollo S; Pezzani R; Cristiani A; Redaelli M; Zambonin L; Rubin B; Bertazza L; Zane M; Mucignat-Caretta C; Bulfone A; Pennelli G; Casal Ide E; Pelizzo MR; Mantero F; Moro S; Mian C
    Thyroid; 2014 May; 24(5):809-19. PubMed ID: 24295088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 68.